A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy.

摘要: The pro-inflammatory cytokine interleukin (IL)-1β is a clinical target in many conditions involving dysregulation of the immune system; therapeutics that block IL-1β have been approved to treat diseases such as rheumatoid arthritis (RA), neonatal onset multisystem inflammatory diseases, cryopyrin-associated periodic syndromes, active systemic juvenile idiopathic arthritis. Here, we report generation and engineering new fully human antibody binds tightly with neutralization potency more than 10 times higher marketed canakinumab. After affinity maturation, derived shows >30-fold increased compared its parent antibody. This anti-human IgG also cross-reacts mouse monkey IL-1β, hence facilitating preclinical development. In number models, this efficiently reduced or abolished signs disease associated pathology. Due high for both vitro vivo, propose novel anti-IL-1β monoclonal promising therapeutic candidate potential alternative current arsenal.